Corporate News
Date | Headline | |
---|---|---|
March 1, 2024 | Minutes of the Extraordinary General Meeting of Shareholders | |
March 1, 2024 | Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis | |
February 8, 2024 | EINLADUNG ZUR AUSSERORDENTLICHEN GENERALVERSAMMLUNG 2024 | |
February 8, 2024 | INVITATION TO THE EXTRAORDINARY GENERAL MEETING |
Date | Headline | |
---|---|---|
July 12, 2023 | Kinarus Therapeutics Announces Personnel Changes | |
June 29, 2023 | Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting | |
June 2, 2023 | Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting | N/A |
February 21, 2023 | Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update | |
January 17, 2023 | Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan |
Date | Headline | |
---|---|---|
December 13, 2021 | Kinarus receives 7 Million CHF Grant from the Swiss Federal Funding Programme for COVID-19 Medicines | |
September 9, 2021 | Kinarus Secures CHF 57 Million Capital Commitment | |
August 23, 2021 | Preclinical Data Confirm Triple Mechanism of Action of Lead Compound KIN001 in COVID-19 | |
August 17, 2021 | Signature of a Memorandum of Understanding with Perfect Holding SA | |
April 26, 2021 | Kinarus further strengthens its leadership with two reputed industry experts | N/A |
April 13, 2021 | First Hospitalized COVID-19 Patient Dosed with KIN001 in Phase 2 Study | |
April 13, 2021 | Kinarus AG: First Hospitalized COVID-19 Patient Dosed with KIN001 in Phase 2 Study | N/A |
January 21, 2021 | Kinarus appoints Thierry Fumeaux, MD, as Chief Medical Officer |